» Articles » PMID: 32449085

Targeted Gene Silencing BRAF Synergized Photothermal Effect Inhibits Hepatoma Cell Growth Using New GAL-GNR-siBRAF Nanosystem

Overview
Publisher Springer
Specialty Biotechnology
Date 2020 May 26
PMID 32449085
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Liver cancer is one of the most common malignancies worldwide. The RAF kinase inhibitors are effective in the treatment of hepatocellular carcinoma (HCC); therefore, inhibition of the BRAF/MEK/ERK pathway has become a new therapeutic strategy for novel HCC therapy. However, targeted specific delivery systems for tumors are still significant obstacle to clinical applications. Galactose (GAL) can target the asialoglycoprotein receptor (ASGPR) that is highly expressed on liver cancer cells. In this study, we designed a novel multifunctional nanomaterial GAL-GNR-siBRAF which consists of three parts, GAL as the liver cancer-targeting moiety, golden nanorods (GNR) offering photothermal capability under near infrared light, and siRNA specifically silencing BRAF (siBRAF). The nanocarrier GAL-GNR-siBRAF showed high siRNA loading capacity and inhibited the degradation of siRNA in serum. Compared with naked gold nanorods, GAL-GNR-siBRAF possessed lower biotoxicity and higher efficacy of gene silencing. Treatment with GAL-GNR-siBRAF significantly downregulated the expression of BRAF and impaired proliferation, migration, and invasion of liver cancer cells. Moreover, combinatorial photothermal effects and BRAF knockdown by GAL-GNR-siBRAF effectively given rise to tumor cell death. Therefore, our study developed a new type of targeted multi-functional nanomaterial GAL-GNR-siBRAF for the treatment of liver cancer, which provides ideas for the development of new clinical treatment methods.

Citing Articles

Therapeutic effect of E-Lip-siRNA-sFlt1 on pre-eclampsia: targeted gene silencing and improved pregnancy outcomes.

Dong J, Zhang Y, Zhou J, Mao S, Tang J, Li S Nanomedicine (Lond). 2024; 19(18-20):1615-1627.

PMID: 39016060 PMC: 11389737. DOI: 10.1080/17435889.2024.2368449.


Understanding Gene Involvement in Hepatocellular Carcinoma: Implications for Gene Therapy and Personalized Medicine.

Younis M, Harashima H Pharmgenomics Pers Med. 2024; 17:193-213.

PMID: 38737776 PMC: 11088404. DOI: 10.2147/PGPM.S431346.


The Role of Small Interfering RNAs in Hepatocellular Carcinoma.

Chen F, Zhang W, Gao X, Yuan H, Liu K J Gastrointest Cancer. 2023; 55(1):26-40.

PMID: 37432548 DOI: 10.1007/s12029-023-00911-w.

References
1.
Li L, Zhao G, Shi Z, Qi L, Zhou L, Fu Z . The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC. Oncol Lett. 2016; 12(5):3045-3050. PMC: 5103898. DOI: 10.3892/ol.2016.5110. View

2.
Mond M, Alexiadis M, Eriksson N, Davis M, Muscat G, Fuller P . Nuclear receptor expression in human differentiated thyroid tumors. Thyroid. 2014; 24(6):1000-11. DOI: 10.1089/thy.2013.0509. View

3.
Li W, Lian Y, Guan Q, Li N, Liang W, Liu W . Liver-targeted delivery of liposome-encapsulated curcumol using galactosylated-stearate. Exp Ther Med. 2018; 16(2):925-930. PMC: 6090458. DOI: 10.3892/etm.2018.6210. View

4.
Colombino M, Sperlongano P, Izzo F, Tatangelo F, Botti G, Lombardi A . BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis. 2012; 3:e259. PMC: 3270270. DOI: 10.1038/cddis.2011.136. View

5.
Dong Z, Huang K, Liao B, Cai H, Dong Y, Huang M . Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation. Eur Radiol. 2018; 29(5):2272-2282. DOI: 10.1007/s00330-018-5882-4. View